Analysts Set BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Price Target at $389.73

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) has received a consensus recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $391.00.

ONC has been the topic of several analyst reports. Wells Fargo & Company began coverage on shares of BeOne Medicines in a research note on Monday. They issued an “overweight” rating and a $400.00 target price on the stock. Guggenheim raised their price target on shares of BeOne Medicines from $410.00 to $420.00 and gave the stock a “buy” rating in a report on Thursday. Jefferies Financial Group cut shares of BeOne Medicines from a “buy” rating to a “hold” rating and decreased their price objective for the company from $420.00 to $290.00 in a research report on Monday, March 16th. Royal Bank Of Canada upped their price objective on shares of BeOne Medicines from $423.00 to $425.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a report on Monday, April 20th.

BeOne Medicines Price Performance

ONC opened at $312.12 on Monday. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.08. The stock’s 50 day simple moving average is $301.40 and its 200 day simple moving average is $322.00. The firm has a market cap of $34.25 billion, a price-to-earnings ratio of 69.83 and a beta of 0.50. BeOne Medicines has a 1 year low of $218.31 and a 1 year high of $385.22.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings data on Wednesday, April 1st. The company reported $0.25 earnings per share for the quarter. The firm had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. As a group, analysts predict that BeOne Medicines will post 5.44 earnings per share for the current year.

Insider Buying and Selling

In other BeOne Medicines news, SVP Chan Henry Lee sold 341 shares of the stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $300.00, for a total value of $102,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.62% of the stock is owned by insiders.

Hedge Funds Weigh In On BeOne Medicines

Hedge funds and other institutional investors have recently made changes to their positions in the business. Mariner LLC lifted its stake in BeOne Medicines by 3.8% in the fourth quarter. Mariner LLC now owns 883 shares of the company’s stock worth $269,000 after acquiring an additional 32 shares during the period. Signaturefd LLC increased its position in BeOne Medicines by 10.7% during the 4th quarter. Signaturefd LLC now owns 340 shares of the company’s stock valued at $103,000 after purchasing an additional 33 shares during the period. Farther Finance Advisors LLC raised its holdings in BeOne Medicines by 21.8% in the 4th quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock worth $66,000 after purchasing an additional 39 shares in the last quarter. CWM LLC raised its holdings in BeOne Medicines by 32.8% in the 4th quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after purchasing an additional 39 shares in the last quarter. Finally, Sequoia Financial Advisors LLC lifted its position in shares of BeOne Medicines by 4.1% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 1,281 shares of the company’s stock worth $436,000 after purchasing an additional 50 shares during the period. Institutional investors own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.